Estella M Janz-Robinson1, Nadia Badawi2, Karen Walker2, Barbara Bajuk3, Mohamed E Abdel-Latif4. 1. Department of Medicine, Canberra Hospital, Garran, Australian Capital Territory, Australia. 2. Grace Centre for Newborn Care, The Children's Hospital at Westmead, Westmead, Australia; Cerebral Palsy Alliance Research Foundation, Notre Dame University, Sydney, Australia; Discipline of Paediatrics and Child Health, Sydney Medical School, University of Sydney, Sydney, Australia. 3. Neonatal Intensive Care Units Data Collection, NSW Pregnancy and Newborn Services Network, Sydney Children's Hospitals Network, Sydney, Australia. 4. Department of Neonatology, Centenary Hospital for Women and Children, Garran, Australian Capital Territory, Australia; Medical School, College of Medicine, Biology & Environment, Australian National University, Acton, Canberra, Australia. Electronic address: Abdel-Latif.Mohamed@act.gov.au.
Abstract
OBJECTIVE: To compare neurodevelopmental outcomes of extremely preterm infants diagnosed with patent ductus arteriosus (PDA) who were treated medically or surgically and those who were not diagnosed with PDA or who did not undergo treatment for PDA. STUDY DESIGN: This retrospective population-based cohort study used data from a geographically defined area in New South Wales and the Australian Capital Territory served by a network of 10 neonatal intensive care units. Patients included all preterm infants born at <29 completed weeks of gestation between 1998 and 2004. Moderate/severe functional disability at 2-3 years corrected age was defined as developmental delay, cerebral palsy requiring aids, sensorineural or conductive deafness (requiring bilateral hearing aids or cochlear implant), or bilateral blindness (best visual acuity of <6/60). RESULTS: Follow-up information at age 2-3 years was available for 1473 infants (74.8%). Compared with infants not diagnosed with a PDA or who did not receive PDA treatment for PDA, those with medically treated PDA (aOR, 1.622; 95% CI, 1.199-2.196) and those with surgically treated PDA (aOR, 2.001; 95% CI, 1.126-3.556) were at significantly greater risk for adverse neurodevelopmental outcomes at age 2-3 years. CONCLUSION: Our results demonstrate that treatment for PDA may be associated with a greater risk of adverse neurodevelopmental outcome at age 2-3 years. This was particularly so among infants born at <25 weeks gestation. These results may support permissive tolerance of PDAs; however, reasons for this association remain to be elucidated through carefully designed prospective trials.
OBJECTIVE: To compare neurodevelopmental outcomes of extremely preterm infants diagnosed with patent ductus arteriosus (PDA) who were treated medically or surgically and those who were not diagnosed with PDA or who did not undergo treatment for PDA. STUDY DESIGN: This retrospective population-based cohort study used data from a geographically defined area in New South Wales and the Australian Capital Territory served by a network of 10 neonatal intensive care units. Patients included all preterm infants born at <29 completed weeks of gestation between 1998 and 2004. Moderate/severe functional disability at 2-3 years corrected age was defined as developmental delay, cerebral palsy requiring aids, sensorineural or conductive deafness (requiring bilateral hearing aids or cochlear implant), or bilateral blindness (best visual acuity of <6/60). RESULTS: Follow-up information at age 2-3 years was available for 1473 infants (74.8%). Compared with infants not diagnosed with a PDA or who did not receive PDA treatment for PDA, those with medically treated PDA (aOR, 1.622; 95% CI, 1.199-2.196) and those with surgically treated PDA (aOR, 2.001; 95% CI, 1.126-3.556) were at significantly greater risk for adverse neurodevelopmental outcomes at age 2-3 years. CONCLUSION: Our results demonstrate that treatment for PDA may be associated with a greater risk of adverse neurodevelopmental outcome at age 2-3 years. This was particularly so among infants born at <25 weeks gestation. These results may support permissive tolerance of PDAs; however, reasons for this association remain to be elucidated through carefully designed prospective trials.
Authors: Dany E Weisz; Lucia Mirea; Erin Rosenberg; Maximus Jang; Linh Ly; Paige T Church; Edmond Kelly; S Joseph Kim; Amish Jain; Patrick J McNamara; Prakesh S Shah Journal: JAMA Pediatr Date: 2017-05-01 Impact factor: 16.193
Authors: Shannon E G Hamrick; Hannes Sallmon; Allison T Rose; Diego Porras; Elaine L Shelton; Jeff Reese; Georg Hansmann Journal: Pediatrics Date: 2020-11 Impact factor: 7.124
Authors: Andrea F Duncan; Carla M Bann; Nathalie L Maitre; Myriam Peralta-Carcelen; Susan R Hintz Journal: J Pediatr Date: 2020-05-28 Impact factor: 4.406
Authors: Carl H Backes; Sharon L Cheatham; Grace M Deyo; Scott Leopold; Molly K Ball; Charles V Smith; Vidu Garg; Ralf J Holzer; John P Cheatham; Darren P Berman Journal: J Am Heart Assoc Date: 2016-02-12 Impact factor: 5.501
Authors: Madeleine L Barnett; Nora Tusor; Gareth Ball; Andrew Chew; Shona Falconer; Paul Aljabar; Jessica A Kimpton; Nigel Kennea; Mary Rutherford; A David Edwards; Serena J Counsell Journal: Neuroimage Clin Date: 2017-11-21 Impact factor: 4.881
Authors: Tomasz Stankowski; Sleiman Sebastian Aboul-Hassan; Farzaneh Seifi-Zinab; Dirk Fritzsche; Marcin Misterski; Ivan Sazdovski; Jakub Marczak; Anna Szymańska; Lukasz Szarpak; Kurt Ruetzler; Sanchit Ahuja; Bartłomiej Perek Journal: J Thorac Dis Date: 2019-06 Impact factor: 2.895